Sugi Predict

Sugi Predict / Compounds / SCHEMBL1763873

SCHEMBL1763873

SCHEMBL1763873

COC(=O)CC[C@H](NC(=O)OC(C)(C)C)C(=O)OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ CTSK P43235 9/20 0.47
▸ CTSS P25774 5/20 0.43
▸ CA2 P00918 3/20 0.43
▸ CA1 P00915 2/20 0.43
▸ CA12 O43570 2/20 0.43
▸ CA9 Q16790 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ CA7 P43166 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ ALOX5 P09917 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ CTSL P07711 2/20 0.40
▸ CTSB P07858 1/20 0.40
▸ NFKB1 P19838 1/20 0.40
▸ NFKB2 Q00653 1/20 0.40
▸ RELA Q04206 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1317487 1.00 CYP1A2 (0.49) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL2225458 1.00 CYP1A2 (0.49) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL2390166 0.94 CYP1A2 (0.49) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL15418649 0.94 CYP1A2 (0.49) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL13076509 0.94 CYP1A2 (0.49) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL8056542 0.91 CTSK (0.51) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL13040188 0.91 CTSK (0.51) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL27847191 0.91 CTSK (0.51) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL11175129 0.90 CYP1A2 (0.42) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL19422705 0.89 CYP1A2 (0.63) CYP1A2CYP2C9CYP2C19HTTCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120136760-A Industrial production method of key intermediate of Nemactevir 沧州那瑞化学科技有限公司 2025-06-13 — — CN claimed
CN-116332801-B Preparation method of N-tert-butoxycarbonyl-L-glutamic acid dimethyl ester derivative 阜阳欣奕华制药科技有限公司 2025-02-18 — — CN claimed
CN-115490626-B Key chiral compound of PF-07321332 and preparation method thereof 杭州科巢生物科技有限公司 2024-08-23 — — CN claimed
CN-115073347-B Preparation method of lactam ring medical intermediate 浙江江北药业有限公司 2024-07-30 — — CN claimed
CN-118324680-A Synthesis method of (alpha S, 3S) -alpha-amino-2-oxo-3-pyrrolidine propionamide hydrochloride 宁波酶赛生物工程有限公司 2024-07-12 — — CN claimed
CN-114605301-B Method for preparing Pa Luo Weide intermediate 江苏恒沛药物科技有限公司 2024-06-04 — — CN claimed
CN-114163347-B Synthesis method of N-acyl glutamate 镇江中智化学科技有限公司 2024-03-26 — — CN claimed
CN-116396191-A Preparation method of N-tert-butoxycarbonyl-L-glutamic acid dimethyl ester derivative 阜阳欣奕华制药科技有限公司 2023-07-07 — — CN claimed
CN-116332801-A Preparation method of N-tert-butoxycarbonyl-L-glutamic acid dimethyl ester derivative 阜阳欣奕华制药科技有限公司 2023-06-27 — — CN claimed
CN-116023302-A Boc-L-glutamic acid dimethyl ester and preparation method thereof 烟台舜康生物科技有限公司 2023-04-28 — — CN claimed
CN-115947670-A Synthesis process of N-tert-butyloxycarbonyl-L-glutamic acid dimethyl ester 常州吉恩药业有限公司 2023-04-11 — — CN claimed
CN-218741950-U Reaction kettle for synthesizing N-tert-butyloxycarbonyl-L-glutamic acid dimethyl ester 镇江中智化学科技有限公司 2023-03-28 — — CN claimed
CN-115490626-A PF-07321332 key chiral compound and preparation method thereof 杭州科巢生物科技有限公司 2022-12-20 — — CN claimed
CN-115073347-A Preparation method of lactam ring pharmaceutical intermediate 浙江江北药业有限公司 2022-09-20 — — CN claimed
CN-114989043-A Synthesis method of boc-L-glutamic acid dimethyl ester 南京红杉生物科技有限公司 2022-09-02 — — CN claimed
CN-114605301-A Method for preparing intermediate of palovir 江苏恒沛药物科技有限公司 2022-06-10 — — CN claimed
CN-114163347-A Synthesis method of N-acyl glutamate 镇江中智化学科技有限公司 2022-03-11 — — CN claimed
US-12636275-B2 Pharmaceutical use of ketoamide-based compound SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2026-05-26 — — US disclosed
WO-2003061653-A1 3-(IMIDAZOLYL)-2-AMINOPROPANOIC ACIDS FOR USE AS TAFI-A INHIBITORS FOR THE TREATMENT OF THROMBOTIC DISEASES PFIZER LIMITED (GB) 2003-07-31 — — WO disclosed
US-6458948-B1 MIXING A QUATERNARY AMMONIUM SALT HAVING A PARTICULAR TRIAZINE RING IN THE MOLECULES THEREOF, A CARBOXYLIC ACID COMPOUND AND A COMPOUND HAVING A NUCLEOPHILIC FUNCTIONAL GROUP, TO CONDENSE THE CARBOXYLIC ACID WITH THE COMPOUND HAVING THE NUCLEOPHILIC TOKUYAMA CORPORATION (JP) 2002-10-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12636275-B2 Pharmaceutical use of ketoamide-based compound CTSV, CTSL, CTSS CYP1A2 740/4885CYP2C9 264/4885CYP2C19 197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.